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Available online 27 November 2015Protein-based vaccines offer a safer alternative to live-attenuated or inactivated vaccines but have limited immu-
nogenicity. The identiﬁcation of adjuvants that augment immunogenicity, speciﬁcally in amanner that is durable
and antigen-speciﬁc, is therefore critical for advanced development. In this study, we use the ﬁlovirus virus-like
particle (VLP) as a model protein-based vaccine in order to evaluate the impact of four candidate vaccine adju-
vants on enhancing long term protection from Ebola virus challenge. Adjuvants tested include poly-ICLC
(Hiltonol), MPLA, CpG 2395, and alhydrogel. We compared and contrasted antibody responses, neutralizing an-
tibody responses, effector T cell responses, and T follicular helper (Tfh) cell frequencies with each adjuvant's im-
pact on durable protection.We demonstrate that in this system, themost effective adjuvant elicits a Th1-skewed
antibody response and strong CD4 T cell responses, including an increase in Tfh frequency. Using immune-
deﬁcient animals and adoptive transfer of serumand cells fromvaccinated animals into naïve animals,we further
demonstrate that serum and CD4 T cells play a critical role in conferring protection within effective vaccination
regimens. These studies inform on the requirements of long term immune protection, which can potentially be
used to guide screening of clinical-grade adjuvants for vaccine clinical development.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Ebola virus1. Introduction
Traditional vaccine development has focused on highly immuno-
genic live-attenuated or inactivated pathogen platforms. However,
safety concerns associated with these platforms, as well as advances in
vaccinemanufacturing and antigen characterization, have turned inter-
est toward protein-based vaccines. Protein-based vaccines are designed
to elicit an immune response against a speciﬁc antigenwith knownpro-
tective capabilities. While they are a safer alternative to traditional vac-
cines, they are also less immunogenic and confer less durable immune
responses. Among protein-based vaccine platforms are virus-likeof differentiation;DSCF, Dwass,
rbent assay; ELISPOT, enzyme-
cell sorting; FBS, fetal bovine
and Use Committee; IM, intra-
; LN, lymph node; ma-EBOV,
A; NAb, neutralizing antibody;
aque forming unit; PRR, pattern
assay; TLR, Toll-like receptor;
te of Infectious Diseases; VLP,
l Research Institute of Infectious
.
. This is an open access article underparticles (VLPs), which are essentially empty viral particles incapable
of replicating in the host. VLPs have been heralded as one of the most
promising future vaccine platforms, and some examples of VLPs are al-
ready in the clinic, including Cervarix, a Human Papilloma Virus (HPV)
vaccine (Pitoiset et al., 2015; Einstein et al., 2014a, 2014b).
Adjuvants are often included in protein-based vaccines in order to reg-
ulate antigen dispersal and to enhance immunogenicity. Recent advances
in adjuvant discovery have highlighted the potential importance of pat-
tern recognition receptor (PRR) ligands as vaccine adjuvants (Coffman
et al., 2010; Steinhagen et al., 2011; Brunner et al., 2010; O'Hagan and
Fox, 2015). Traditional alum-based vaccine adjuvants may not work for
vaccines requiring a cytotoxic, Th1-skewed immune response, whereas
PRR agonists can be used to direct the type of immune response elicited
against the vaccine antigen. AS04, an aluminumsalt adjuvant that includes
the Toll-like receptor (TLR) 4 ligandmonophosphoryl lipid A, has been ap-
proved in Fendrix andCervarix,Hepatitis B andHPVvaccines, respectively,
and several other PRR agonist-based adjuvants are currently in clinical
trials (Surquin et al., 2011; Beran, 2008; Einstein et al., 2014a, 2014b).
In this study, four adjuvants were tested in combination with the
Ebola virus VLP vaccine to determine their impact on durable protec-
tion. Alhydrogel is a well-characterized aluminum hydroxide adjuvant,
which is currently in several FDA-approved vaccines. Alhydrogel pro-
vides a depot effect whereby antigen is released more slowly in vivo,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ute to adjuvantcy (Hutchison et al., 2012). Additionally, alhydrogel has
been shown to activate the inﬂammasome, which may contribute to
the immunogenicity of alhydrogel-based vaccines (Guven et al., 2013;
Gupta, 1998; Hogenesch, 2002; Marrack et al., 2009). PolyICLC is a
double-strandRNA stabilized bypoly-L-lysine in carboxymethylcellulose
(Levy et al., 1975). It signals through TLR3 and potentially MDA5
receptors, eliciting a strong type I IFN response, and it skews the immune
response toward a Th1 proﬁle response (Wang et al., 2010; Alexopoulou
et al., 2001; Nemes et al., 1969). PolyICLC has been inmultiple clinical tri-
als for both therapeutic and vaccine purposes (Martins et al., 2015b).
There are three different classes of CpGmolecules, which target different
cell subsets and receptors and have different recognition in mouse and
human cells (Verthelyi et al., 2001; Hartmann et al., 2003; Marshall
et al., 2003). The CpG examined here is a class C CpG (2395), meaning
that it signals through both pDC and B cells, impacting type I IFN produc-
tion, antigen-presenting cell (APC) maturation, and NK cell activation
(Marshall et al., 2003). CpG molecules (speciﬁcally 7909) have been in
multiple clinical trials as vaccine adjuvants; the speciﬁc CpG tested in
this work has not been in clinical trials but was selected as it targets
both human and murine TLR9 and it has both Class A and B activation
characteristics. Finally, MPLA is a TLR4 agonist, which is comparable to
MPL, the active component of the GSK adjuvant AS04 (Einstein et al.,
2014a, 2014b). MPLA has been shown to be highly effective as an adju-
vant, particularly in combination with an aluminum-based adjuvant
like alhydrogel or a nanoparticle formulation (Bohannon et al., 2013).
Considerable work has gone into evaluating the impact of putative
adjuvants on innate immune activation and on adaptive immune re-
sponses to model antigens and potential vaccines (Longhi et al., 2009;
Kastenmuller et al., 2012; Trumpfheller et al., 2008; Stahl-Hennig
et al., 2009; Perret et al., 2013; Caproni et al., 2012). It has been
demonstrated that co-administration of adjuvant and antigen can be
critical for optimizing the immune response, and formulation of adju-
vants and antigen in nanoparticles for co-administration is currently
being explored as a means of targeting the adjuvant effects (Quinn
et al., 2013b; Hanson et al., 2015; Moon et al., 2012; Jain et al., 2011).
However, adjuvants' impact on long lasting protective immunity is
poorly understood, particularly in the context of a relevant challenge
model (Seder et al., 2015).
The ﬁlovirus VLP vaccine has demonstrated efﬁcacy in the murine,
guinea pig, and nonhuman primate models of ﬁlovirus infection
(Swenson et al., 2005, 2008a, 2008b; Warﬁeld et al., 2003, 2004, 2007;
Martins et al., 2014, 2015a). To evaluate durable protection, we devel-
oped a rigorousmurinemodel for Ebola virus challenge.We then tested
the ability of the aforementioned adjuvants to augment protection
under this model. Correlates of durable protection were identiﬁed by
comparing and contrasting immune parameters associated with differ-
ent levels of protection. These data informbroadly on the impact of clas-
sic TLR agonists to enhance the durable protection of a protein-based
vaccine, and they demonstrate that adjuvant selection can determine
the quality and utility of a vaccine candidate.
2. Methods
2.1. Ethics Statement
Researchwas conducted under an IACUC approved protocol in com-
pliancewith the AnimalWelfare Act, PHS Policy, and other Federal stat-
utes and regulations relating to animals and experiments involving
animals. The IACUC committee approving this protocol is the United
States Army Medical Research Institute of Infectious Diseases
(USAMRIID) IACUC. The facility where this research was conducted,
USAMRIID, is accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care, International and adheres to
principles stated in the 8th Edition of the Guide for the Care and Use
of Laboratory Animals, National Research Council, 2011.2.2. Animals, Vaccinations, and Viral Challenge
C57BL/6micewere obtained fromNCI Charles River.Mice between8
and 12 weeks of age were vaccinated with 100 μl via the intramuscular
(IM) route, in the caudal thigh. All mice in each study were female and
age-matched and thereforewere inherently randomized. For studies in-
volving CD8-deﬁcient animals (Jackson Laboratory strain 002665) and
CD4-deﬁcient animals (Jackson Laboratory strain 002663), C57BL/6J
(Jackson Laboratory strain 000664) mice were used as controls.
Animals were monitored at least once daily by technical staff mem-
bers who were blinded to the study aims. Animal status was evaluated
according to an Intervention Scoresheet approved by USAMRIID
IACUC. Monitoring increased to three times daily if the animals were
given a score of three or four. Euthanization was by CO2 inhalation
followed by conﬁrmatory cervical dislocation. Analgesics and anes-
theticswere not used in this study, and animalswere euthanized for hu-
mane purposes if they reached a score of ﬁve or more, which would be
indicated if the animals exhibited rufﬂed fur, weakness, unresponsive-
ness, and/or difﬁculty walking. Otherwise, animals were euthanized
on day 14 of the study. For all survival studies, control groups included
animals vaccinated with saline and/or adjuvant alone.
MPLA (MPLA-SM; extracted from LPS produced by Salmonella
minnesota R595) and CpG (CpG 2395 Class C, vac-2395-1; 5′-
tcgtcgttttcggcgc:gcgccg-3′) were from Invivogen and polyICLC
(Hiltonol) was provided by Oncovir, Inc.; these adjuvants were diluted
with sterile saline after resuspension in DMSO (MPLA) or water
(CpG). Alhydrogel was from Brenntag (CAS #21645-51-2, 10 mg/ml
stock) and was diluted with sterile PBS. VLPs were manufactured by
Paragon Bioservices and were produced by transfecting HEK293F cells
with Ebola Zaire virus GP and VP40 genes in pWRG expression
vectors, essentially as previously described (Swenson et al., 2004). VLP
were irradiated at 1e6 rad to ensure sterility and contained less than
25 EU/ml endotoxin and less than 10 colony forming units of bacteria
per vaccination. Vaccines were administered IM two times, with
3 weeks between vaccinations. A challenge dose of 1000 pfu of
mouse-adapted (ma-) Ebola virus was administered via the intraperito-
neal (IP) route (Bray et al., 1998). The mouse model of Ebola virus chal-
lenge is awell-documented small animalmodel of Ebola virus challenge
and recapitulates someof the symptoms of human Ebola virus infection.
It has been used to evaluate multiple vaccines and therapeutics devel-
oped against ﬁloviruses.
2.3. Adoptive Transfer Studies
C57BL/6micewere vaccinated two timeswith threeweeks between
vaccinations. Four weeks after the second vaccination, serum and
splenocytes were harvested. Negatively selected (“untouched”) T cells
(Miltenyi Biotech, 130-095-130), CD4 T cells (Miltenyi Biotech, 130-
104-454), or CD8 T cells (Miltenyi Biotech, 130-104-075) were isolated
using magnetic separation in accordance with the manufacturer's in-
structions. Cell purity was universally greater than 90% and on average
94%. Cells and serumwere combined prior to injection IP into recipient
mice. Twenty-four hours after transfer, mice were challenged IP with
1000 pfu of ma-EBOV.
2.4. Antibody Assays
Antibody titers were determined using an ELISA. Two μg/ml of re-
combinant Ebola virus GPwas plated in a ﬂat bottom96well plate over-
night. Plateswere incubatedwith blockingbuffer (5%milk, 0.05%Tween
in PBS) for 2 h, and then serum samples were added to plates. The stan-
dard protocol used half log dilutions starting at a 1:100 dilution. After
2 h, plates were washed with PBS + 0.05% Tween and secondary anti-
body was added at a 0.6 μg/ml. Secondary antibodies included goat
anti-mouse IgG-HRP (Southern Biotech 1030–05), IgG1-HRP (Southern
Biotech 1070–05), IgG2c-HRP (Southern Biotech 1079–05), and IgG3-
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and exposed using Sure Blue TMB 1-component substrate and stop so-
lution (KPL), and the absorbance at 450 nm was recorded. Serum from
unvaccinated animals was used to establish background and titers
were deﬁned as the serum dilution resulting in an absorbance greater
than 0.2, where background was universally less than 0.2. Serum from
animals previously determined to contain anti-GP antibodywas includ-
ed in each assay to serve as a positive control.
2.5. Pseudovirion Neutralization Assay
The pseudovirion neutralization assay (PsVNA) used to detect neu-
tralizing antibodies in sera was essentially described previously; it
uses a replication-restricted, recombinant vesicular stomatitis virus
(rVSV*ΔG) expressing luciferase, which is pseudotyped with the Ebola
GP (Kikwit) (Martins et al., 2015a). Brieﬂy, heat-inactivated mouse
sera was ﬁrst diluted 1:20, followed by ﬁve-fold serial dilutions that
were mixed with an equal volume of Eagle's minimum essential medi-
um with Earle's salts and 10% fetal bovine sera (FBS) containing 4000
ﬂuorescent focus units (FFU) of EBOV-95 pseudovirions and 10% guinea
pig complement (Cedarlane). Thismixturewas incubated overnight at 4
°C. Following this incubation, 50 μl was inoculated onto Vero cell mono-
layers in a clear bottom, black-walled 96-well plate in duplicate. Plates
were incubated at 37 °C for 18–24 h. The media was discarded and
cells were lysed according to the luciferase kit protocol (Promega
#E2820). A Tecan M200 Pro was used to acquire luciferase data. The
values were graphed using GraphPad Prism software and used to calcu-
late the percent neutralization using cells alone and pseudovirions
alone, using the minimum and maximum signals, respectively. Maxi-
mum signal was controlled on a per plate basis to reduce signal varia-
tion. The curves generated were interpolated to obtain PsVNA 50 and
80% neutralization titers.
2.6. T Cell Assays — Intracellular Cytokine Staining
Mice were euthanized by CO2 inhalation at various time points after
vaccination and splenocytes were harvested for T cell assays. After red
blood cell lysis, cells were cultured at 10e6 cells/ml in complete media
(90% RPMI 1640, 10% FBS, 20 mM Hepes, 1% Pen/strep, 0.05 mM BME)
with 10 U/ml mouse recombinant IL2, 1 μg/ml mouse CD49d (BD
#553,314), 1 μg/mlmouse CD28 (BD 553295), and 1× protein transport
inhibitor cocktail (eBioscience #00–4980). 1e6 cells were plated in each
well of a 96 well plate and were stimulated with either cell stimulation
cocktail (eBioscience 00-4970-93) as a staining control, DMSO, or Ebola
virus peptides at 2 μg/ml. Ebola virus GP peptide WIPYFGPAAEGIYTE
(WE15) was utilized for experimental samples as it had previously
been shown to elicit a detectable T cell response in C57BL/6 mice
(Olinger et al., 2005; Shedlock et al., 2013).
Six hours after stimulation, cells were washed in PBS + 10% FBS.
Live/Dead aqua (Invitrogen)was used to identify viable cells by incuba-
tion for 10min at 4 °C, and Fc Block (Miltenyi)was used to prevent non-
speciﬁc antibody binding. After washing, surface antibodies CD3-FITC
(BD clone 145-2C11), CD8-APC-H7 (BD clone 53–6.7), CD4-PacBlue
(BD clone RM4-5) were incubated with samples for 20′ at 4C, and
then cells were washed again and ﬁxed with 3.7% paraformaldehyde
overnight. Cells were then permeabilized with perm/wash (eBioscience
00-8333-56) and stained with IFNγ-APC (BD clone XMG1.2), IL2-PECy7
(BD clone JES6-5H4), and TNFα-PE (BD clone MP6-XT22) antibodies.
Cells were run on the Canto II ﬂow cytometer, and analysis was con-
ducted using FlowJo software. Isotype controls and minus one controls
were used to deﬁne populations.
2.7. T Cell Assays — Sorting of T Cell Memory Populations
Four weeks after the second vaccination, splenocytes were harvest-
ed from C57BL/6mice and subjected to red blood cell lysis. Untouched Tcells were isolated bymagnetic bead separation, in accordance with the
manufacturer's instructions (Miltenyi Biotech, 130-095-130). Cells
were stained with CD44 (BD Clone IM7) and CD62L (L-Selectin, BD
CloneMEL-14) to identify central and effectormemory cell populations,
as well as Live/Dead aqua (Invitrogen) (Henao-Tamayo et al., 2010;
Hikono et al., 2007; Lefrancois and Masopust, 2002; Krishnan et al.,
2007). Cells were then washed two times and sorted on the BD Aria II.
Purity of sorted populations was conﬁrmed on the BD Canto II and cell
purity was universally greater than 95% for each T cell sub-population
added to culture.
Feeder cells were isolated from splenocytes of naïve C57BL/6 mice.
CD3+ T cells were depleted using magnetic bead isolation (Miltenyi
Biotech 130-094-973) in accordance with the manufacturer's instruc-
tions. Puritywas conﬁrmedon the BDCanto II and cellswere universally
greater than 95% CD3 negative.
Feeder cells were plated at 5e5 cells/well in 100 μl of media with
20 U/ml mouse recombinant IL2, 2 μg/ml mouse CD49d (BD Clone
9C10), 2 μg/ml mouse CD28 (BD Clone 37.51), and 0.2 μM GP. Sorted T
cells were added at 1e5-2e5 cells/well in 100 μl. Cells were cultured
for four days; on the third day, 50 μl/well of media with 40 U/ml of IL2
was added to eachwell. On the fourth day of culture, cells were pelleted
and subjected to intracellular cytokine staining, as described above.
2.8. ELISPOT Assay
MabTechMouse IFNγ ELISPOT PLUS kit (3321-2HW-Plus) was used
for evaluation of IFNγ production. Cells were pre-plated overnight with
capture antibody, as per the manufacturer's instructions. Splenocytes
were isolated from vaccinated animals and subjected to red blood cell
lysis. Cells were then resuspended at 2e6/ml and 100 μl of cells was
combinedwith 100 μl of stimulationmastermix.Mastermixes included
20 U/ml mouse recombinant IL2, 2 μg/ml mouse CD49d (BD 553314),
2 μg/mlmouse CD28 (BD 553295), and one of the following stimulants:
4 μg/mlWE15 peptide, 0.2 μMGP, or 4 μg/ml DMSO. Cells were incubat-
ed in ELISPOT plates for 16 h at 37 °C, and the ELISPOT assay was con-
ducted as per the manufacturer's instructions. Plates were analyzed
using the CTL ImmunoSpot reader. Values were calculated by averaging
duplicate wells and then subtracting the average of the unstimulated
duplicate wells for each animal.
2.9. Popliteal Lymph Node Isolation for Transcriptomic Analysis
Popliteal lymph nodes (LN) were isolated from vaccinated mice
seven days after vaccination. LN were ﬁltered on a 70 μm ﬁlter and re-
suspended in PBS. Untouched T cells were isolated by magnetic bead
separation, in accordance with the manufacturer's instructions
(Miltenyi Biotech, 130-095-130). Cells were then lysed with buffer
RLT and RNA was isolated using the Qiagen RNeasy Mini Kit, according
to themanufacturer's instructions (Qiagen 74104). RNA from 3 to 4 an-
imals per vaccination group was pooled and analyzed using the
SABiosciences PCR Array (T cell and B cell activation array, PAMM-
053Z) on an ABI 7900 HT real time PCR instrument, in triplicate. Ct
values were normalized to housekeeping genes and the fold difference
in expression of genes in the T cells of animals vaccinated with VLP
and polyICLC vs. VLP alone was determined.
2.10. Popliteal Lymph Isolation and Identiﬁcation of T Follicular Helper Cell
Populations
Popliteal LN were isolated from vaccinated mice 7 days after vacci-
nation. LN were ﬁltered on a 70 μm ﬁlter and resuspended in PBS.
Cells were plated in 96 well plates and viable cells were identiﬁed
using Invitrogen's Live/Dead aqua dye. T follicular helper (Tfh) cell pop-
ulationswere identiﬁed by surface stainingwith CD3, CD4, CXCR5, ICOS,
and PD1 as well as intracellular staining for Bcl6.
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mouse CXCR5 (BD Clone 2G8) at 1:100 in buffer A (PBS + 0.5%
BSA + 0.1% sodium azide supplemented with 2% normal mouse
serum (NMS) and 2% FCS) for 1 h. Cells were then washed two times
and incubated with goat anti-rat (H + L)-biotin (Jackson
ImmunoResearch, 112-067-003) in buffer A for 30 min. Cells were
then washed twice and incubated with streptavidin-PECy7 (BD
557598), anti-CD3-V450 (BD Clone 500A2), anti-CD4-PerCyCy5.5 (BD
Clone RM4-5), anti-PD1-APC (eBioscience Clone RMP1-30), and anti-
ICOS-PE (BD Clone 7E.17G9) in buffer A for a further 30 min. After two
more washes, cells were incubated with BD Phosﬂow Lyse/Fix buffer
(BD 558049) for 12 min at 37 °C, washed two times, and incubated
with anti-Bcl6-Alexa488 (BD Clone K112-91) for 1 h in Perm/Wash
Buffer I (BD 557885). Cells were washed two times and examined on
the BD FACS Canto II.
2.11. Statistical Analysis
Statistical analyses were performed using SAS Version 9.4 (2012 SAS
Institute, Cary, NC). Continuous variables were screened for normality
and homogeneity of variance. IgG, IgG1, IgG2c, IgG3, T-cell responses,
cytokines, chemokines, and splenocytes were analyzed by nonparamet-
ric methods. In instanceswheremultiple group comparisons using non-
parametric methods were required, Kruskal–Wallis tests were initially
used followed by the Dwass, Steel, Critchlow-Fligner (DSCF) multiple
pairwise comparison procedure to control the familywise error rate. In
instances where only two-sample comparisons were required, Mann–
Whitney–Wilcoxon rank-sum tests were used, and, where required,
stepdown Bonferroni corrections were used to control the familywise
error rate. Neutralizing antibody titers met assumption of normality
and homogeneity of variance and were analyzed using one-way analy-
sis of variance (ANOVA) with post-hoc Tukey's studentized range tests
for pairwise comparisons. Percentage surviving between groups was
compared using Fisher's exact tests. In instances where multiple
pairwise survival comparisonswere required, stepdownBonferroni cor-
rections were used to control the familywise error rate. Cochran-
Armitage test for trend was used to evaluate survival across groupsFig. 1. Adjuvants impact the durability of protection conferred by eVLP vaccination. (a) C57BL/6
weeks or twenty-two (long-term) weeks after the vaccine boost. Data in A are pooled from 8
group was signiﬁcantly higher than in the long-term group (p b 0.0001). (b) C57BL/6 mice we
the second vaccination. n = 9 or 10/group. Cochran-Armitage test: percentage surviving decli
0.03) between survival on Day 77 and Day 175. (c) Serum samples collected from animals in
IgG, IgG1, and IgG2c antibody titers. Red symbols indicate titers of animals that succumbed to
that one of these two animals succumbed to challenge, but animal tagswere indeterminate after
VLP, with or without the indicated adjuvants. Animals were challenged twenty-two weeks afte
least 35 animals per group. P-values comparing VLP alone to vaccinationwith VLP and adjuvant
VLP, VP = VLP + PolyICLC, VC = VLP + CpG, VM= VLP +MPLA, and VA= VLP + alhydrogwith increasing time to challenge. For IgG and IgG1, values below the
lower limits of detection (LLOD) (100) were set to a value equal to the
LLOD divided by the square root of 2 (100/√2). For IgG2c and IgG3,
values below the lower limits of detection (LLOD) (10) were set to a
value equal to the LLODdivided by the square root of 2 (10/√2). For neu-
tralizing antibody titers, values below the lower limits of detection
(LLOD) (40) were set to a value equal to the LLOD divided by the square
root of 2 (40/√2).
3. Results
3.1. Adjuvants can Enhance the Duration of Vaccine-Mediated Protection
We previously demonstrated that VLP expressing GP and VP40 of
Ebola Zaire can confer protection from ma-EBOV challenge in C57BL/6
mice. Inclusion of adjuvant provided vaccine dose-sparing, but the du-
rability of the protective immune response was unclear (Martins et al.,
2014). To test the efﬁcacy of VLP vaccination in a durable challenge
model, we vaccinated mice two times with 10 μg of VLP, a dose level
that is protective when challenge occurs 4 weeks after vaccine boost.
We then challenged the animals 22 weeks after the vaccine boost. One
hundred percent of animals challenged on the short-term schedule sur-
vived challenge, as anticipated; however, only 37.5% (24/64) of animals
challenged 22 weeks after vaccination survived (Fig. 1a) (p b 0.0001).
Using a serial challenge strategy, we vaccinated animals as before and
then challenged 8weeks, 12weeks, 18weeks, or 22weeks after the sec-
ond vaccination. We observed that protection declined as the length of
time from vaccination to challenge increased (Fig. 1b) (p = 0.0046).
This decline was concurrent with a drop in antibody titer, and signiﬁ-
cant differences between challenge days, regardless of survival status,
were found for IgG (p = 0.0002), IgG1 (p = 0.0005), and IgG2c (p =
0.0009). The sample sizes were insufﬁcient to compare survivors and
non-survivors within each challenge day, however (Fig. 1c).
We next evaluated whether inclusion of adjuvants could augment
durable protection. Using data from short-term challenges, we identi-
ﬁed the dose level of adjuvant that could provide dose-sparing on the
short term schedule. We then evaluated the efﬁcacy of that dose levelmice were vaccinated IM two times with 10 μg of eVLP and challenged four (short-term)
individual studies with 6–10 animals/group. Fisher's exact test: survival in the short-term
re vaccinated IM two times with 10 μg of eVLP and challenged at the indicated days after
ned as time to challenge increased (p = 0.0046). There was a signiﬁcant difference (p =
(B) one week prior to challenge were subjected to an ELISA for the evaluation of anti-GP
challenge while black indicate titers of survivors; red symbols with black outlines indicate
challenge.Median and IQR shown. (d) C57BL/6micewere vaccinated two times (IM)with
r the vaccine boost. Data in D are pooled from at least 4 separate studies with a total of at
are shown, calculated using Fisher's exact tests with stepdown Bonferroni correction. V=
el.
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were vaccinated with 10 μg of VLP alone or in combination with 10 μg
of polyICLC, MPLA, CpG ODN, or 10% alhydrogel. As shown in Fig. 1d, in-
clusion of polyICLC rescued VLP-mediated durable protection, resulting
in 100% survival, and this was a signiﬁcant increase compared to surviv-
al after vaccinationwith VLP alone (p b 0.0001). Inclusion of CpG result-
ed in an increase in survival compared to VLP alone, but this was not
signiﬁcant (p = 0.179). Inclusion of MPLA or alhydrogel had no impact
on survival. These data provided a clear basis by which effective and in-
effective vaccination regimens could be evaluated, permitting the iden-
tiﬁcation of correlates of immune protection.
3.2. Adjuvants Associated with Durable Protection Elicit a Th1 IgG Response
Antigen-speciﬁc IgG titers are frequently used as a correlate of
vaccine-mediated protection, including in some EBOV challengemodels
(Wong et al., 2012). The efﬁcacy of the rVSV-ZEBOV vaccine appears to
be highly dependent upon antibody, for example, and anti-GP antibod-
ies have been used successfully as therapeutics in NHPmodels of infec-
tion (Wong et al., 2012, 2014; Qiu et al., 2012; Dye et al., 2012). In the
present study, all four adjuvants signiﬁcantly enhanced anti-GP IgG an-
tibody titers by Day 35 when compared to vaccination with VLP alone,
with p-values less than 0.0017 (Fig. 2a,b). By Day 168, 1 week prior to
challenge, titers after vaccination with polyICLC, MPLA, or alhydrogel
were still signiﬁcantly higher than titers after vaccination with VLP
alone (p b 0.04), but titers from animals vaccinated with VLP and CpG
were comparable to those of animals vaccinated with VLP alone.
The subclass of IgG signiﬁcantly impacts the function of the anti-
body. In C57BL/6 mice, a Th2 skewed immune response is marked by
higher IgG1 titers while a Th1 skewed immune response is marked by
high IgG2c and IgG3 titers; these isotypes were therefore selected for
analysis (Finkelman et al., 1988; Snapper and Paul, 1987). There were
many statistically signiﬁcant differences between vaccination groups
(Fig. 2b), and the overall trends are presented in Fig. 2c.Mice vaccinated
with VLP and alhydrogel had signiﬁcantly higher IgG1 titers than mice
vaccinated VLP alone or VLP with CpG, and this was true at both time
points. In contrast, these same mice had the lowest IgG2c and IgG3 ti-
ters, in keeping with the published observation that alhydrogel elicits
a Th2 skewed immune response. In contrast, animals vaccinated with
VLP and polyICLC, the vaccination regimen that conferred protection,
had the highest IgG2c titers of all groups at both time points (p b 0.015).
In order to determine whether antibody neutralization was impact-
ed by the inclusion of adjuvants, we evaluated neutralization using the
PsVNA, which measures neutralization of pseudoparticles expressing
Ebola GP. At the early time point, serum from animals vaccinated with
VLP and polyICLC had signiﬁcantly higher NAb titers as compared to
VLP alone or VLP administered with any other adjuvant (p b 0.0001)
(Fig. 2d). At the late time point, vaccinationwith VLP and alhydrogel in-
duced the highest NAb titers on average, despite the fact that alhydrogel
had no beneﬁcial impact on survival. Titers in animals vaccinated with
VLP and alhydrogel were signiﬁcantly higher than those of VLP with
MPL or CpG on day 168 (p b 0.04).
3.3. Adjuvants Associated with Durable Protection Elicit Antigen-Speciﬁc
CD4 and CD8 T Cell Responses
VLP-mediated protection from Ebola virus challenge has been asso-
ciated with the presence of antigen-speciﬁc T cell responses as well as
antibody. To evaluate the impact of the adjuvants on overall IFNγ T
cell responses, we euthanized mice 4 days after the vaccine boost and
evaluated IFNγ production via ELISPOT analysis. For the antigen, we uti-
lized a known CD4 and CD8 T cell epitope, the peptide WE15, as de-
scribed in the Methods section (Fig. 3a). Additionally, we used full-
length recombinant GP as the antigen in a duplicate set of experiments,
and we observed the same pattern of IFNγ production regardless of the
antigen used (Fig. 3a and Supplemental Fig. 1).ELISPOT data indicated that polyICLC induced the highest frequency
of IFNγ producing cells, which was signiﬁcantly higher than the fre-
quency of cells elicited by VLP vaccination alone or with any other adju-
vants (p b 0.04) (Fig. 3a). Vaccination with CpG and VLP elicited the
second highest IFNγ response, which was approximately half that ob-
served with VLP and polyICLC. To determine whether the response ob-
served after vaccinationwith VLP and polyICLC or CpGwasCD4 or CD8 T
cell mediated, we performed intracellular cytokine staining on
splenocytes on day 4 after the vaccine boost. Cells from animals vacci-
nated with VLP and polyICLC or VLP and CpG were evaluated and, in
keeping with the ELISPOT results, we observed that polyICLC elicited
higher frequencies of antigen-speciﬁc IFNγ-producing cells than CpG,
though this was not signiﬁcant, as well as higher frequencies of TNFα-
producing CD4 T cells (p = 0.0209) (Fig. 3b,c).
In order to evaluate the persistence of this T cell response, we vacci-
nated mice two times, and then we left them to rest for 22 weeks. At
that time, whenwewould normally challenge for the durable challenge
model, we administered a third vaccine boost and then euthanized an-
imals 4 days later. We performed ELISPOT analysis on splenocytes from
these animals and observed, as anticipated, a lower overall frequency of
IFNγ-producing cells as compared to Day 4 after the boost (Fig. 3d).
However, animals vaccinated with VLP and polyICLC still had signiﬁ-
cantly higher frequencies of antigen-speciﬁc cells as compared to ani-
mals vaccinated with VLP alone or VLP with alhydrogel (p b 0.05).
We next hypothesized that the inclusion of adjuvants may impact
not only the frequency of antigen-speciﬁc T cells, but also the memory
phenotype. The frequency of antigen-speciﬁc T cells in vaccinated
mice is quite low after the peak response. We therefore developed an
assay to sort and culture memory T cells. Four weeks after vaccination,
we puriﬁed and cultured the CD44highCD62L+ (central memory),
CD44highCD62L- (effector memory), and CD44low/int (antigen-inex-
perienced) cell populations using FACS (Fig. 3e). We evaluated the fre-
quency of antigen-speciﬁc CD4 vs. CD8 T cells that expanded from
each sorted population and found that while CD44low/int cells failed
to expand in response to antigen-pulsed feeder cells, both central and
effector memory cell populations did expand (Fig. 3f). Regardless of
the inclusion of adjuvant, there was a strong bias toward central mem-
ory cells being predominantly CD8 T cells while effector memory cells
were predominantly CD4 T cells. No clear difference between the adju-
vants was observed. Additionally, no clear impact on the skewing of the
central vs. effector memory populations by adjuvants was observed in
either CD4 or CD8 T cells.
Overall our studies found that the frequency of antigen-speciﬁc T
cells appeared to correlate with efﬁcacy, but the speciﬁc role of CD4
and CD8 T cells was unclear. To further understand the relevance of
CD8 T cells, we examined vaccination in CD8-deﬁcient mice.
3.4. CD8 T Cells are not Required for VLP-Mediated Protection, with or
without Adjuvants
Protection against some pathogens, including HIV-1, malaria, and
even inﬂuenza, is associated not only with antibody responses but
with the frequency of Th1 proﬁle, cytotoxic T cell responses (Watkins,
2008; Doll and Harty, 2014; Sridhar et al., 2013; Mendoza et al., 2013;
Quinn et al., 2013a). CD8 T cell responsesmay also be critical for protec-
tion mediated by the adenovirus-based Ebola vaccine (Sullivan et al.,
2011), although other ﬁlovirus vaccines do not appear to require an
antigen-speciﬁc CD8 T cell response (Rao et al., 2002; Marzi et al.,
2013; Wong et al., 2012). To evaluate whether the presence of
antigen-speciﬁc CD8 T cells is necessary for VLP-mediated durable pro-
tection, we vaccinated C57BL/6J mice and CD8-deﬁcient mice with VLP,
with or without polyICLC or CpG. Animals were challenged four weeks
or twenty-two weeks after the vaccine boost. The lack of CD8 T cells
had no effect on animal survival or on anti-GP IgG titers. All vaccinated
animals survived short term challenge, with the exception of one CD8
deﬁcient animal vaccinated with VLP alone (Fig. 4a). Additionally, in
Fig. 2.Adjuvants have variable impact on IgG subclasses and antibody neutralization. (a) Serumwas collected 14 days and 147 days after the vaccine boost (days 35 and 168, respectively)
and evaluated for anti-GP IgG, IgG1, IgG2c, and IgG3 levels using an ELISA. Data shown are pooled from at least two separate experiments per group. (b) Pairwise comparison using DSCF
multiple pairwise comparisonwas used and p values greater than 0.05 are shown as “ns”. (c) Summary of results shown inA, B andD. (d)Neutralizing antibody titerswere evaluatedusing
the PsVNA, with titers giving 80% neutralization shown; median and IQR shown. Samples within each group were selected randomly from three separate studies for evaluation in the
assay. Pairwise comparison using post-hoc Tukey's studentized range test procedure was used to evaluate differences between groups at both days 35 and day 168, where
“*” indicates 0.01 b p b 0.05, “**” indicates 0.001 b p b 0.01, “***” indicates 0.0001 b p b 0.001, and “****” indicates p b 0.0001.
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and polyICLC and 90% (9/10) of animals vaccinated with VLP and CpG
survived, as did 44% (4/9) of C57BL/6J animals vaccinated with VLP
alone and 30% (3/10) of CD8-deﬁcient animals vaccinated with VLP
alone (Fig. 4b). Notably, it appears that CpG was more effective in this
C57BL/6J strain than in the C57BL/6 mice used for other studies;nonetheless, the trends between the CD8-deﬁcient animals and the
control animals were comparable.
To determine whether a compensatory immune response was
accounting for survival in the CD8-deﬁcient animals, we examined
antigen-speciﬁc antibody and CD4 T cell frequencies. Anti-GP IgG titers
between CD8-deﬁcient animals and C57BL/6J animals did not differ at
Fig. 3. Effective adjuvants increase the frequency of antigen-speciﬁc T cells. (a) IFNγ ELISPOT analysis of splenocytes from C57BL/6 mice vaccinated two times with indicated vaccine and
adjuvant combination. Splenocytes were collected on day 4 after the second vaccination. Data is pooled from four separate experiments each containing 2–3mice per group;medianwith
IQR shown. (B&C) Frequency of IFNγ+, IL2+, or TNFα+cells after vaccinationwith VLP andpolyICLC orVLP andCpG;median shown.Gating is on viable T cells and then CD4+CD44high
T cells (b) or CD8+ CD44high T cells (c). (d) IFNγ ELISPOT analysis of splenocytes from C57BL/6mice vaccinatedwith indicated vaccine and adjuvant combination. Animals received the
standard two vaccinations and then received a third vaccine boost 22 weeks after the second vaccination. Splenocytes were collected 4 days later. Data is pooled from two separate ex-
periments each containing 3–4 mice per group; median with IQR shown. (e) Four weeks after the second vaccination, splenocytes were collected from animals and T cells were isolated
using negative bead selection. T cells were then sorted to collect central memory, effector memory, and CD44int/low cell populations. Gating strategy is shown. (f) Sorted T cells were
culturedwith peptide-exposed, T cell-depleted, naïve splenocytes and the frequency of cytokine-positive CD4 and CD8 T cells in each sorted populationwas quantiﬁed after 5 days of cul-
ture. Gating is on CD4 or CD8 T cells and data shown are the frequency of cells expressing IFNγ, TNFα, or IL2; median is shown. “*” indicates 0.01 b p b 0.05.
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in the frequency of antigen-speciﬁc CD4 T cells between mouse strains
(Fig. 4d). These data suggest that the survival observed in the
CD8-deﬁcient animals was not attributable to a compensatory increase
in the CD4 T cell population or an enhanced antibody response due to
potentially higher frequencies of helper CD4 T cells, and they imply
that CD8 T cells are not required for VLP-mediated protection in the
mouse model.
3.5. Adjuvants Associated with Durable Protection Enhance Tfh Cell
Frequency
In our study, the protective vaccination regimen resulted in an in-
crease in the frequency of antigen-speciﬁc, cytokine-positive CD4 T
cells (Fig. 3b). Additionally, CD4-deﬁcient animals did not surviveupon vaccination with VLP alone (p b 0.0001 comparing survival of
C57BL/6J vs CD4−/−) and these animals were largely incapable of
mounting an IgG response upon VLP vaccination, suggesting that anti-
body class switch recombination was T cell dependent (Supplemental
Fig. 2).
In order to take a more global look at factors differentiating T cells
after vaccination with VLP as compared to VLP and polyICLC, we vacci-
nated mice and isolated draining popliteal LN seven days after vaccina-
tion. Untouched T cells were isolated from the lymph nodes using bead
depletion, andRNAwas isolated, pooled, and subjected to analysis using
the SABioscience T-cell and B-cell Activation Array (PAMM-053Z). Five
transcripts were up-regulated more than two-fold in T cells from ani-
mals vaccinated with VLP and polyICLC as compared to VLP alone,
with p values less than 0.05 (Fig. 5a). CXCR5 was one of these tran-
scripts, and it was increased with a p-value of 0.0002. CXCR5 is
Fig. 4. CD8 T cell deﬁciency does not impact short term or long term survival of vaccinated C57BL/6J mice. (a) Mice were treated IM twice with saline, VLP, VLP and polyICLC, or VLP and
CpG. Four weeks after the second vaccination, mice were challenged. Closed symbols represent wild type C57BL/6J mice and open symbols indicate CD8-deﬁcient mice. (b) Mice were
vaccinated on the same schedule as in A, but challenge occurred 22 weeks after the second vaccination. (c) Two weeks after the second vaccination and 1 week prior to challenge,
blood was collected from vaccinated animals and evaluated for anti-GP IgG antibody titers. (D) A subset of vaccinated animals was euthanized 4 days after the vaccine boost to evaluate
CD4+T cell responses.Median response of C57BL/6Jmice and CD8-deﬁcientmice is shown.N=8–10per treated group for A–C andDpresents data pooled from two separate evaluations
of 4–8 mice per group each. “*” indicates 0.005 b p b 0.05.
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class switch recombination.
To explore the impact of adjuvants on Tfh expansion, we vaccinated
animals with adjuvant alone, VLP alone, or VLP in combination with
each of the TLR agonist adjuvants. Seven days after vaccination, we eu-
thanized mice and examined the frequency of Tfh cells (CXCR5+PD1+)
in the draining popliteal LN. These cells expressed elevated ICOS and
Bcl6 in comparison to CXCR5− cells. Animals vaccinated with VLP and
polyICLC had signiﬁcantly higher frequencies of this cell population
than those vaccinated with VLP alone (p= 0.0276), while animals vac-
cinated with VLP in combination with either MPLA or CpG exhibited in-
termediate frequencies of Tfh cells (Fig. 5b-c). These data point to a
critical helper role for CD4 T cells in durable vaccination, whichmay ac-
count for the robust IgG responses observed in this model.
3.6. Adoptive Transfer of T Cells and Serum from Vaccinated Animals
Confers Protection from Challenge
Having established that T cell responses were impacted by inclusion
of protective adjuvants both in terms of cytokine-producing antigen-
speciﬁc T cells and the frequency of Tfh,we examinedwhether adoptive
transfer of T cells from vaccinated animals into naïve mice could confer
protection from Ebola virus challenge. Cells and serum were collected
from vaccinated animals 4 weeks after the second vaccination. T cellsubsets were isolated by negative depletion so as to minimize inadver-
tent activation of T cells prior to transfer. Cells and serum, alone or in
combination, were transferred into naïve mice (IP) 24 h prior to virus
challenge.
As shown in Table 1, transfer of cells or serum from animals vacci-
nated with VLP alone had no impact on the survival of the recipient an-
imals. Additionally, transfer of serum alone or splenocytes alone from
animals vaccinated with VLP and polyICLC had no impact on the surviv-
al of the recipient animals. However, combining serum with cells from
animals vaccinated with VLP and polyICLC was capable of rescuing sur-
vival, and transfer of as few as 5e6 splenocytes from vaccinated animals
rescued survival in ~90% (9/10) of recipient animals (Table 1). To deter-
minewhether T cells were important for the cellular aspect of conferred
protection, 5e6 T cells from VLP and polyICLC-vaccinated animals were
transferred to naïve animals, with or without serum (Table 2). Not sur-
prisingly, the T cells alone were unable to confer protection from chal-
lenge; however, 89% (8/9) of animals receiving serum and 5e6 T cells
survived challenge. Again, transfer of cells and serum from animals vac-
cinated with VLP alone was not protective.
Data obtained from vaccination studies with CD8-deﬁcient animals
(Fig. 4) and the statistically signiﬁcant increase in CD4 effector cells
upon vaccination with VLP and polyICLC as compared to VLP and CpG
(Fig. 3) led us to hypothesize that CD4 T cells would be critical for pro-
tection from challenge. To test this hypothesis, 4e6 CD4 or CD8 T cells
Fig. 5.Tfh frequencies are increasedby adjuvants associatedwith protection from challenge. C57BL/6micewere vaccinated a single time IMwith VLP,with orwithout adjuvant. Seven days
after vaccination, the draining popliteal LNwas isolated. (a) Untouched T cells were isolated from the LN (n=3 or 4/group). RNAwas isolated from the puriﬁed T cells and pooled for each
vaccination group. Samples were then evaluated using the SABiosciences T and B cell activation PCR array in triplicate. For the volcano plot, the fold difference is the average of triplicate,
and the p value was calculated comparing animals vaccinatedwith VLP to those vaccinatedwith VLP and polyICLC. (b) Seven days after vaccination, cells from the draining LNwere eval-
uated for Tfh populations. Cells were gated on viable lymphocytes after doublet exclusion, and then on CD4+ T cells expressing CXCR5 and PD1. Median and IQR shown.
(c) CD3 + CD4 + CXCR5 + PD1+ cell population in mice vaccinated with VLP and polyICLC. ICOS and Bcl6 expression of this population is shown. Data shown are pooled from three
separate vaccination experiments. Comparisons between animals receiving VLP with or with adjuvant are shown, where “*” indicates 0.01 b p b 0.05 (Kruskal–Wallis test).
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naïve animals. Ninety-two percent of animals receiving CD4 T cells
and serum survived challenge while none of the animals receiving
CD8 T cells and serum survived. To determine whether increasing the
number of transferred CD8 T cells would impact the result, 12e6 CD8
T cells were transferred with serum; this combination protected 60%Table 1
Adoptive transfer of bulk splenocytes and serum from vaccinated animals to naïve animals.
Group Transfer group (donor animals) Number of cells Cell type Serum (μl)
1
PolyICLC +VLP
5e6 Splenocytes 200
2 20e6 Splenocytes 200
3 20e6 Splenocytes n/a
4 n/a n/a 200
5
VLP
5e6 Splenocytes 200
6 20e6 Splenocytes 200
7 20e6 Splenocytes 500
8 n/a n/a n/a n/a
a Pooled frommultiple iterationswith n=4 to 10 per iteration. Fisher's exact testwith Bonfe
vs. 4 (p = 0.006), 1 vs. 5 (p = 0.006), 2 vs. 3 (p = 0.0005), and 2 vs. 6 (0.0044).(3/5) of recipient animals (Table 2). These data suggest that the fre-
quency of transferred cells is critical for mediating protection. Finally,
to determine whether CD4 T cells from animals vaccinated with VLP
and CpG could confer protection, serum and 4e6 CD4 T cells were trans-
ferred into naïve animals. Eighty percent of recipient animals survived
challenge (Table 2).Number of animalsa Percent survival Challenge material Challenge dose level
10a 90
Ma-EBOV 1000 pfu
24a 83
10a 0
5 0
5 0
5 0
3 0
60a 0
rroni correction, pairwise comparisonswere used to evaluate Group 1 vs. 2 (p=0.3819), 1
Table 2
Adoptive transfer of puriﬁed T cells from vaccinated animals to naïve animals.
Group Transfer group (donor animals) Number of cells Cell type Serum (μl) Number of animalsa Percent survival Challenge material Challenge dose level
1
PolyICLC+VLP
5e6 T cells 200 9a 89
Ma-EBOV 1000 pfu
2 5e6 T cells n/a 10a 0
3 4e6 CD4+T cells 200 25a 92
4 4e6 CD8+T cells 200 9a 0
5 12e6 CD8+T cells 200 5 60
6 VLP 5e6 T cells 200 5 0
7 CpG + VLP 4e6 CD4+T cells 200 5 80
a Pooled frommultiple iterationswith n=4 to 10 per iteration. Fisher's exact testwith Bonferroni correction, pairwise comparisonswere used to evaluate Group 1 vs. 2 (p=0.0005), 3
vs. 4 (p = 0.0005), 4 vs. 5 (p = 0.055), 7 vs. 3 (p = 0.4335), and 1 vs. 6 (0.009).
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Protein-based vaccines offer a safe and effective means to achieve
protection from a variety of pathogens, but their poor immunogenicity
makes inclusion of an adjuvant imperative. In addition to enhancing im-
munogenicity, adjuvants can provide dose sparing and impact the re-
quired vaccination schedule. In this study, we examined the impact of
adjuvants on the durability of a model protein-based vaccine, the ﬁlovi-
rus VLP.
Of the adjuvants tested in this system, polyICLC had the most bene-
ﬁcial impact on durable protection. However, vaccination with VLP and
polyICLC impacted nearly every immune parameter tested, including
NAb titers, Th1-skewed antibody titers, CD8 T cell responses, CD4 T
cell responses, and Tfh cell responses. To delineate the relative impor-
tance of these immune parameters, we compared effects elicited by
polyICLC to those elicited by the less effective antigen and adjuvant
combinations.
In terms of antibody response, a Th1-skewed antibody response cor-
related with protection. Vaccination with VLP and polyICLC yielded sig-
niﬁcantly higher IgG2c titers than vaccination with any other vaccine
and adjuvant combination. In contrast, vaccination with alhydrogel
and VLP, which had no impact on survival, resulted in a Th2 skewed an-
tibody response. To further examine the impact of antibody on survival,
NAb titers were examined. NAb are associated with protection in sever-
al vaccinationmodels (Roy et al., 2015; van Gils and Sanders, 2014; Kok
et al., 2014; Plotkin, 2010), but data regarding the importance of NAb in
EBOV protection are conﬂicting (Wong et al., 2012; Sullivan et al., 2009;
Audet et al., 2014; Oswald et al., 2007; Grant-Klein et al., 2015; Lee et al.,
2008; Bale et al., 2012; Martins et al., 2015a; Agnandji et al., 2015). In-
terestingly, NAb titers had no relationship to survival in this durable
protection model. Both polyICLC and alhydrogel substantially impacted
NAb titers and improved survival on a short term timescale; however,
only polyICLC had a beneﬁcial impact on durable protection. This exam-
ination of antibody feeds into a larger discussion on the role of neutral-
ization and the deﬁnition of neutralizing antibody. The assay utilized in
this study includes supplementation with complement, which compli-
cates the deﬁnition of neutralization. Despite this fact, neutralization
still did not correlate with survival while IgG2c titers did, suggesting
an under-appreciated role for non-neutralizing antibody in controlling
infection under a durable protection model.
Previous work has demonstrated that CD4 T cells may be important
for Ebola-mediated protection (Wong et al., 2012; Rao et al., 2002).
However, dissecting the role of CD4 T cells in protective immunity is
challenging due to their impact on the development of high afﬁnity an-
tibody responses and effective CD8 T cell responses (Sant and
McMichael, 2012). CD4 T cells also have an effector function and are
critical for immune cell recruitment during infection (Soghoian and
Streeck, 2010; McKinstry et al., 2012; Brown et al., 2012; Johnson
et al., 2015). Recently, an appreciation for the importance of CD4 T
cells in viral infection has grown, particularly in the context of inﬂuenza
vaccination (Zens and Farber, 2015). Antigen-speciﬁc CD4 T cells were
associated with lower viremia during human inﬂuenza infection
(Wilkinson et al., 2012), and, in nonhuman primates, CD4 T cellpopulations were important in Hepatitis A clearance (Zhou et al.,
2012). Because of the complex role of CD4 T cells in the immune re-
sponse, the impact of adjuvants on CD4 T cell responses has also been
extensively examined (Baumgartner and Malherbe, 2010; McAleer
and Vella, 2010). Both TLR agonist adjuvants and aluminum-
containing adjuvants have been associated with CD4 T cell efﬁcacy
(Monaci et al., 2015; Sokolovska et al., 2007).
Three compelling sets of data from our studies suggest that, in com-
bination with a Th1-skewed antibody response, CD4 T cells correlate
with VLP-mediated protection under a durable protection murine
model. First, the frequency of IFNγ-producing T cells was signiﬁcantly
higher in the protective adjuvant vaccination (polyICLC + VLP) than
the partially protective (CpG + VLP) or unadjuvanted vaccination, and
these cells were predominantly CD4 T cells. Second, transcriptomic
analysis of T cells from animals vaccinated with the protective vaccine
revealed up-regulation of CXCR5 as compared to vaccination with VLP
alone. This observation led us to examine the frequency of Tfh cells in
thedraining lymphnode,wherewe observed that polyICLC signiﬁcantly
enhanced the frequency of Tfh cells over the suboptimal vaccinations.
Third, adoptive transfer of CD4 T cells from animals vaccinated with
VLP and polyICLC, in combinationwith serum,was protective at cell fre-
quencies as low as 4e6 whereas three times as many CD8 T cells were
required for comparable protection. In combination, these data suggest
that it is not simply the impact of CD4T cells on B cellmaturation or CD8
T cell development that makes CD4 T cells critical for vaccine-mediated
protection, but that the actual presence of antigen-speciﬁc CD4 T cells is
relevant for protection from challenge.
The data presented here informbroadly on how the tested adjuvants
impact the immune response to a protein antigen. Moreover, by testing
these adjuvants in a challengemodel, the data inform on the speciﬁc re-
quirements for long term protection fromma-EBOV challenge. Describ-
ing the immune proﬁle of these canonical TLR agonists may help direct
adjuvant discovery work targeted at achieving long-lasting, vaccine-
mediated protection.
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